As of Wednesday close, Pacira BioSciences Inc.’s (NASDAQ:PCRX) stock was up $0.69, moving up 1.43 percent to $48.96. The average number of shares traded per day over the past five days has been 320,260 shares. 3 times new highs have been achieved over the past 5 days, with a $0.99 gain in that time frame. In the last twenty days, the average volume was 438,960, while in the previous 50 days, it was 395,196.
Since last month, PCRX stock retreated -6.99%. Shares of the company fell to $46.03 on 11/16/22, the lowest level in the past month. A 52-week high of $82.16 was reached on 04/08/22 after having rallying from a 52-week low of $46.03. Since the beginning of this year, PCRX’s stock price has dropped by -18.63% or -$11.21, and marked a new high 19 times. However, the stock has declined by -40.41% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
PCRX stock investors should be aware that Pacira BioSciences Inc. (PCRX) stock had its last reported insider trading activity 48 days ago on Oct 07. REINHARDT MAX, the President, Rest of World of the company, disposed of 1,380 shares for $58.00 on Oct 07. It resulted in a $80,040 divestment by the insider. WINSTON ROY sold 476 shares at an average price of $55.70 on Aug 03. The insider now owns 44,992 shares following the transaction. On Aug 03, Chief Clinical Officer SLONIN JONATHAN sold 308 shares at $55.70 apiece. The transaction was valued at $17,156.
Right now, Pacira BioSciences Inc. (PCRX) has a P/E ratio of about 123.64. The stock’s beta is 0.71. Besides these, the trailing price-to-sales (P/S) ratio of 3.33, the price-to-book (PB) ratio of 2.91, and the price-to-cash flow ratio of 23.47 may also be considered.
In the three months ended September 29, Pacira BioSciences Inc.’s quick ratio stood at 3.30, while its current ratio was 4.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.93, and the total debt-to-equity ratio was 0.97. On the profitability front, the trailing twelve-month gross margin is 73.00% percent. In the year ended September 29, operating margins totaled 11.30%. Based on annual data, PCRX earned $401.28 million in gross profit and brought in $541.53 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 4.20%. Return on equity (ROE) for the past 12 months was 2.80%.
In Pacira BioSciences Inc.’s quarter-end financial report for September 29, it reported total debt of $309.85 million against cash and short-term investments of $219.3 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. PCRX’s revenue rose 23.74% to $169.41 million during the quarter, while net income inched up to $167.47 million. While analysts expected Pacira BioSciences Inc. to report $0.76 quarterly earnings, the actual figure was $0.64 per share, beating the consensus estimate by -15.80%. During the quarter, the company generated $43.09 million in EBITDA. The liabilities of Pacira BioSciences Inc. were 964.24 million at the end of its most recent quarter ended September 29, and its total debt was $821.64 million. The value of shareholders’ equity is $45.88 million.
This quick technical analysis looks at Pacira BioSciences Inc.’s (PCRX) price momentum. With a historical volatility rate of 35.06%, the RSI 9-day stood at 43.74% on 23 November.
With respect to its five-day moving average, the current Pacira BioSciences Inc. price is up by +2.06% percent or $0.99. At present, PCRX shares trade -8.21% below its 20-day simple moving average and -16.09% percent below its 100-day simple moving average. However, the stock is currently trading approximately -10.59% below its SMA50 and -23.14% below its SMA200.
Stochastic coefficient K was 36.31% and Stochastic coefficient D was 35.38%, while ATR was 2.11. Given the Stochastic reading of 40.19% for the 14-day period, the RSI (14) reading has been calculated as 43.10%. As of today, the MACD Oscillator reading stands at -0.71, while the 14-day reading stands at -1.07.
Pacira BioSciences Inc. (PCRX) has been rated Buy by analysts. According to 0 brokerage firms, PCRX is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Pacira BioSciences Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $74.00, the current consensus forecast for the stock is $54.00 – $90.00. Based on these forecasts, analysts predict Pacira BioSciences Inc. (PCRX) will achieve an average price target of $73.55.